Expression of metallothionein-III in patients with non-small cell lung cancer

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 965-974

  Werynska, Bozena ^a   Pula, Bartosz ^a   Muszczynska Bernhard, Beata ^b   Gomulkiewicz, Agnieszka ^a   Jethon, Aleksandra ^a   Podhorska Okolow, Marzena ^a   Jankowska, Renata ^a   Dziegiel, Piotr ^a,c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Laboratory of Histopathology   (Poland)

^c UNIVERSITY OF WROC AW   (Poland)

Author keywords

Growthinhibitory factor; Metallothionein; Non small cell lung cancer

Indexed keywords

KI 67 ANTIGEN; MESSENGER RNA; METALLOTHIONEIN III;

ADULT; ARTICLE; CANCER CELL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL NUCLEUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; RNA, MESSENGER;

EID: 84875904336     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60(5): 277-300, 2010.
2. Margoshes M and Valle BC: A cadmium-binding protein for equine kidney cortex. J Am Chem Soc 79: 4813-4814, 1957.
3. Coyle P, Philcox JC, Carey LC and Rofe AM: Metallothionein: The multipurpose protein. Cell Mol Life Sci 59: 627-647, 2002.
4. Dziegiel P: Expression of metallothioneins in tumor cells. Pol J Pathol 55: 3-12, 2004.
5. De Lisle RC, Sarras MP Jr., Hidalgo J and Andrews GK: Metallothionein is a component of exocrine pancreas secretion: Implications for zinc homeostasis. Am J Physiol 271: 1103-1110, 1996.
6. Gewinner W and Grone HJ: Role of reactive oxygen species in glomerolonephritis. Nephrol Dial Transpl 15: 1127-1132, 2000.
7. Dziegiel P, Suder E, Surowiak P, Kornafel J and Zabel M: Expression of metallothionein in synovial sarcoma cells. Appl Immunohistochem Mol Morphol 10: 357-362, 2002.
8. Dziegiel P, Jelen M, Muszczynska B, Maciejczyk A, Szulc A, Podhorska-Okolow M, Cegielski M and Zabel M: Role of metallothionein expression in non-small cell lung Carcinomas. Rocz Akad Med Bialymst 49: 43-45, 2004.
9. Pastuszewski W, Dziegiel P, Krecicki T, Podhorska-Okolow M, Ciesielska U, Gorzynska E and Zabel M: Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Res 27: 335-342, 2007.
10. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J, Jelen M, Tarkowski R, Wlodarska I, Spytkowska B, Gisterek I, Matkowski R and Kornafel J: Prognostic significance of nuclear and cytoplasmic expression of metallothioneins as related to proliferative activity in squamous cell carcinomas of oral cavity. Histol Histopathol 23: 843-851, 2008.
11. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J, Jelen M, Tarkowski R, Spytkowska B, Matkowski R and Kornafel J: Correlation of metallothionein expression with clinical progression of cancer in oral cavity. Anticancer Res 29: 589-596, 2009.
12. Werynska B, Pula B, Muszczynska-Bernhard B, Piotrowska A, Jethon A, Podhorska-Okolow M, Dziegiel P and Jankowska R: Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in nonsmall cell lung cancer. Anticancer Res 31: 2833-2840, 2011.
13. Wojnar A, Pula B, Piotrowska A, Jethon A, Kujawa K, Kobierzycki C, Rys J, Podhorska-Okolow M and Dziegiel P: Correlation of intensity of MT-I/II expression with Ki-67 and MCM-2 proteins in invasive ductal breast carcinoma. Anticancer Res 31: 3027-3033, 2011.
14. Gomulkiewicz A, Podhorska-Okolow M, Szulc R, Smorag Z, Wojnar A, Zabel M and Dziegiel P: Correlation between metallothionein (MT) expression and selected prognostic factors in ductal breast cancers. Folia Histochem Cytobiol 48: 242-248, 2010.
15. Werynska B, Pula B, Muszczynska-Bernhard B, Gomulkiewicz A, Piotrowska A, Prus R, Podhorska-Okolow M, Jankowska R and Dziegiel P: Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients. Exp Mol Pathol 94: 301-308, 2013.
16. Cherian MG, Jayasurya A and Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533: 201-209, 2003.
17. Santon A, Albergoni V, Sturniolo GC and Irato P: Evoluation of MT expression and detection of apoptotic cells in LEC rat kidney. Biochim Biophys Acta 1668: 223-231, 2004.
18. Quaife CJ, Findley SD, Ericson JC, Froelick GJ, Kelly EJ, Zambrowicz BP and Palmiter RD: Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry 33: 7250-7259, 1994.
19. Uchida Y, Takio K, Titani K, Ihara Y and Tomonaga M: The growth-inhibitory factor that is deficient in Alzheimer's disease is a amino acid metallothionein-like protein. Neuron 7: 337-347, 1991.
20. Tsuji S, Kobayashi H, Uchida Y, Ihara Y and Miyatake T: Molecular cloning of human growth inhibitory factor cDNA and its down-regulation in Alzheimer's disease. EMBO J 11: 4843-4850, 1992.
21. Carrasco J, Adlard P, Cotman C, Quintana A, Penkowa M, Xu F, Van Nostrand WE and Hidalgo J: Metallotionein -I and -III expression in animal models of Alzheimer disease. Neuroscience 143: 911-922, 2006.
22. Ghazi IE, Martin BL and Armitage IM: New proteins found interacting with brain metallothionein-3 are linked to secretion. Int J Alzheimers Dis 2011: 208634, 2011.
23. Meloni G, Faller P and Vasak M: Redox silencing of copper in metal-linked neurodegenerative disorders: Reaction of Zn7 metallotionein-3 with Cu2 ions. J Biol Chem 22: 16068-16078, 2007.
24. Garrett SH, Sens MA, Shukla D, Nestor S, Somji S, Todd JH and Sens DA: Metallothionein isoform 3 expression in the human prostate and cancer-derived cell lines. Prostate 41: 196-202, 1999.
25. Garrett SH, Sens MA, Todd JH, Somji S and Sens DA: Expression of MT-3 in the human kidney. Toxicol Lett 105: 207-214, 1999.
26. Sens MA, Somji S, Lamm DL, Garrett SH, Slovinsky F, Todd JH and Sens DA: Metallothionein isoform 3 as a potential biomarker for human bladder cancer. Environ Health Perspect 108: 413-418, 2000.
27. Sens MA, Somji S, Garrett SH and Sens DA: Metallothionein isoform 3 (MT-3) overexpression is associated with breast cancers having a poor prognosis. Am J Pathol 159: 21-26, 2001.
28. Deng D, El-Rifai W, Ji J, Zhu B, Trampont P, Li J, Smith MF and Powel SM: Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. Carcinogenesis 24: 25-29, 2003.
29. Smith E, Drew P, Tian Z, De Young N, Liu J, Mayne G, Ruszkiewicz A, Watson D and Jamieson G: Metallothionein 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer 4: 42, 2005.
30. Somji S, Garrrett SH, Zhou XD, Zheng Y, Sens DA and Sens MA: Absence of metallothionein 3 expression in breast cancer is a rare, but favorable marker of outcome that is under epigenetic control. Toxicol Environ Chem 92: 1673-1695, 2010.
31. Surowiak P, Materna V, Maciejczyk A, Pudelko M, Markwitz E, Spaczynski M, Dietel M, Zabel M and Lage H: Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 450: 279-285, 2007.
32. Dutta R, Sens DA, Somji S, Sens MA and Garrett SH: Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells. Prostate 52: 89-97, 2002.
33. Karotki AV and Vasak M: Reaction of human metallothionein-3 with cisplatin and transplatin. J Biol Inorg Chem 14: 1129-1138, 2009.
34. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer. Pathologe 8: 138-140, 1987.
35. Romero-Isart N, Jensen LT, Zerbe O, Winge DR and Vasak M: Engineering of metallothionein-3 neuroinhibitory activity into the inactive isoform metallothionein-1. J Biol Chem 277: 37023-37028, 2002.
36. Chen Y, Irie Y, Keung WM and Maret W: S-Nitrosothiols react preferentially with zinc thiolate clusters of metallothionein III through transnitrosation. Biochemistry 41: 8360-8367, 2002.
37. Ding ZC, Zheng Q, Cai B, Yu WH, Teng XC, Wang Y, Zhou GM, Wu HM, Sun HZ, Zhang MJ and Huang ZX: Effect of alpha-domain substitution on the structure, property and function of human neuronal growth inhibitory factor. J Biol Inorg Chem 12: 1173-1179, 2007.
38. Zheng Q, Yang WM, Yu WH, Cai B, Teng XC, Xie Y, Sun HZ, Zhang MJ and Huang ZX: The effect of the EAAEAE insert on the property of human metallothionein-3. Protein Eng 16: 865-870, 2003.
39. Wei H, Desouki MM, Lin S, Xiao D, Franklin RB and Feng P: Differential expression of metallothioneins (MTs) 1, 2 and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Mol Cancer 7: 7, 2008.
40. Hart BA, Voss GW and Vacek PM: Metallothionein in human lung carcinoma. Cancer Lett 75: 121-128, 1993.
41. Theocharis S, Karkantaris C, Philipides T, Agapitos E, Gika A, Margeli A, Kittas C and Koutselinis A: Expression of metallothionein in lung carcinoma: correlation with histological type and grade. Histopathology 40: 143-151, 2002.
42. Faraonio R, Moffatt P, LaRochelle O, Schipper HM, S-Arnaud R and Seguin C: Characterization of cis-acting elements in the promoter of the mouse metallothionein-3 gene activation of gene expression during neuronal differentiation of P19 embryonal carcinoma cells. Eur J Biochem 267: 1743-1753, 2000.